NanoPass Technologies

About NanoPass Technologies

Established in 2000, NanoPass Technologies Ltd. operates from Ness Ziona, Israel, as a medical technology company focused on intradermal drug delivery. The company was founded by Dr. Shuki Yeshurun, a multidisciplinary scientist with extensive experience in R&D, who previously held senior roles at RAFAEL and founded other technology companies like Tortech Nano Fibers. Dr. Yeshurun's background in advanced materials and his D.Sc. from the Technion Institute of Technology have been foundational to the company's technological pursuits.

The core of NanoPass's offering is the MicronJet™, a single-use microneedle device for intradermal delivery. This product, leveraging Micro-Electro-Mechanical Systems (MEMS) technology, features a distinctive design with three hollow pyramids made of pure silicon crystal. It is engineered to deliver substances at a consistent depth of 600 micrometers, targeting the skin's immune-rich environment. This precision allows for improved immunogenicity and dose-sparing for vaccines, as demonstrated in over 70 clinical studies. For instance, research has shown the technology can achieve an equivalent or superior immune response with as little as one-fifth of a standard vaccine dose. The device's applications span vaccines, immunotherapies for cancer and allergies, and aesthetic medicine for treatments like mesotherapy and PRP therapy.

NanoPass operates a dual business model targeting both the pharmaceutical and medical aesthetics markets. In the aesthetics sector, the company utilizes a network of distributors and enters into private label agreements with established brands. For the vaccine and drug delivery market, NanoPass engages in clinical collaborations with major pharmaceutical companies, research institutions like the NIH and CDC, and biotech firms to develop enhanced delivery systems for their products. The company generates revenue through these partnerships and the sale of its MicronJet™ devices. The technology has secured regulatory clearance from the FDA in the U.S. and is also approved in Europe, China, and other key markets.

The company's leadership team includes CEO Daniel Levitats, who brings over 25 years of experience from the high-tech and medical device sectors. Dr. Yotam Levin, who previously served as CEO for many years and holds an MD and an MBA, now acts as President of Innovation. NanoPass has successfully raised a total of $14.9 million over five funding rounds. Its investor base includes prominent names such as Israel HealthCare Ventures (IHCV), West Pharmaceutical Services, and Awz Ventures, which led a recent $6 million funding round in July 2024 to expand the company's commercial reach.